Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.070
0.00 (0.00%)
At close: Aug 1, 2025, 4:00 PM
1.090
+0.020 (1.87%)
After-hours: Aug 1, 2025, 7:45 PM EDT
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $1.26M in the quarter ending March 31, 2025, with 11.68% growth. This brings the company's revenue in the last twelve months to $31.21M, up 1,251.21% year-over-year. In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth.
Revenue (ttm)
$31.21M
Revenue Growth
+1,251.21%
P/S Ratio
11.97
Revenue / Employee
$303,039
Employees
103
Market Cap
388.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LXRX News
- 1 day ago - Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 9 days ago - Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 14 days ago - Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) - GlobeNewsWire
- 5 weeks ago - Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) - GlobeNewsWire
- 6 weeks ago - Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - GlobeNewsWire
- 2 months ago - Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology - GlobeNewsWire
- 2 months ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript - Seeking Alpha